<Anchor>
India, called the'World Vaccine Factory', has stopped exporting AstraZeneca vaccines.
It has no choice but to affect Korea, but reporter Kim Hyung-rae will explain what the situation of the vaccines Korea has secured and whether there will be any disruptions in the vaccination plan.
<Reporter> In
the case of AstraZeneca vaccine, which India has stopped exporting, most of the supply in Korea is produced by consignment.
There is no problem with getting the vaccine right away, but we cannot be relieved.
This is because 100% of vaccine raw materials are imported.
Even if the supply of raw materials decreases due to increased competition for vaccine acquisition, it may affect domestic consignment production.
There is also a report that the supply of the Janssen vaccine in the United States, which Korea has decided to introduce 6 million people, could only reach less than 500,000 people in the first half of this year.
An official from the Vaccination Response Promotion Team said, "We are still discussing the amount and timing of supply."
Health officials say the goal of vaccinating 70% of the people by the end of November remains unchanged.
First, the government plans to complete the first dose of 12 million people by June.
However, only 5.33 million AstraZeneca and 3.56 million Pfizers received confirmation from vaccine companies until June.
To inoculate 12 million people, about 3.1 million more are needed.
You must receive insufficient supplies from the other three companies, Janssen, Moder, and Novabacks.
These companies only announced that they would supply a total of 46 million people each in the second quarter, but they did not disclose how much they would send in which month.
The government is monitoring the international vaccine supply and plans to hurry to establish a schedule for the introduction of these vaccines.